Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

被引：0
|
作者：
F. J. Esteva
Y. V. Baranau
V. Baryash
A. Manikhas
V. Moiseyenko
G. Dzagnidze
E. Zhavrid
D. Boliukh
D. Stroyakovskiy
J. Pikiel
A. E. Eniu
R. K. Li
A. V. Rusyn
B. Tiangco
S. J. Lee
S. Young Lee
S. Y. Yu
J. Stebbing
机构：
[1] NYU Langone Health,Perlmutter Cancer Center
[2] New York University Langone Medical Center,Department of Oncology
[3] Belarusian State Medical University,Division of Cancer
[4] City Clinical Oncology Dispensary,Imperial College Healthcare NHS Trust
[5] GBUZ Saint Petersburg Clinical Research Center of Specialised Types of Care (Oncology),undefined
[6] S. Khechinashvili University Clinic,undefined
[7] Ltd,undefined
[8] N.N. Alexandrov National Cancer Centre of Belarus,undefined
[9] Vinnytsya Regional Clinical Oncology Dispensary,undefined
[10] Moscow City Oncology Hospital,undefined
[11] Wojewodzkie Centrum Onkologii,undefined
[12] Cancer Institute “Ion Chiricuta”,undefined
[13] St. Luke’s Medical Center,undefined
[14] Transcarpathian Regional Clinical Oncology Dispensary,undefined
[15] The Medical City,undefined
[16] CELLTRION,undefined
[17] Inc.,undefined
[18] Imperial Centre for Translational and Experimental Medicine,undefined
[19] Charing Cross Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab; Biosimilar; CT-P6; HER2 positive; Adjuvant; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：839 / 847
页数：8
相关论文
共 50 条
  • [21] HER2-positive Breast Cancer ESMO 2018: Use of Trastuzumab Biosimilar CT-P6 enables High Cost Savings
    不详
    BREAST CARE, 2018, 13 (06) : 463 - 463
  • [22] 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
    Stebbing, J.
    Baranau, Y.
    Baryash, V.
    Manikhas, A.
    Moiseyenko, V.
    Dzagnidze, G.
    Zhavrid, E.
    Boliukh, D.
    Stroyakovskiy, D.
    Pikiel, J.
    Eniu, A.
    Komov, D.
    Lee, S. J.
    Kim, M. J.
    Kim, S.
    Park, S.
    Bae, J. H.
    Esteva, F. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 63 - +
  • [23] Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
    Jackisch, C.
    Kim, S. -B.
    Semiglazov, V.
    Melichar, B.
    Pivot, X.
    Hillenbach, C.
    Stroyakovskiy, D.
    Lum, B. L.
    Elliott, R.
    Weber, H. A.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 320 - 325
  • [24] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    LANCET, 2012, 379 (9816): : 633 - 640
  • [25] Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
    Esteva, F. J.
    Baranau, Y.
    Baryash, V.
    Manikhas, A.
    Moiseyenko, V.
    Dzagnidze, G.
    Zhavrid, E.
    Boliukh, D.
    Stroyakovskiy, D.
    Pikiel, J.
    Eniu, A.
    Komov, D.
    Zautashvili, Z.
    Morar-Bolba, G.
    Li, R. K.
    Lifirenko, I.
    Rusyn, A.
    Lee, S. J.
    Yu, S.
    Stebbing, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] 24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
    Esteva, F. J.
    Lee, S.
    Yu, S.
    Kim, M.
    Kim, N.
    Stebbing, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] Clinical development of CT-P6 in HER2 positive breast cancer
    Fu, Chen
    Stebbing, Justin
    Esteva, Francisco J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 987 - 992
  • [28] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
    Hurvitz, Sara
    Hegg, Roberto
    Chung, Wei-Pang
    Im, Seock-Ah
    Jacot, William
    Ganju, Vinod
    Chiu, Joanne Win Yang
    Xu, Binghe
    Hamilton, Erika
    Madhusudan, Srinivasan
    Iwata, Hiroji
    Altintas, Sevilay
    Henning, Jan-Willem
    Curigliano, Giuseppe
    Perez-Garcia, Jose Manuel
    Egorov, Anton
    Liu, Yali
    Cathcart, Jillian
    Ashfaque, Shahid
    Cortes, Javier
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
    Papakonstantinou, Antroula
    Matikas, Alexios
    Bengtsson, Nils Olof
    Malmstrom, Per
    Hedayati, Elham
    Steger, Guenther
    Untch, Michael
    Hubbert, Laila
    Johansson, Hemming
    Hellstrom, Mats
    Gnant, Michael
    Loibl, Sibylle
    Greil, Richard
    Moebus, Volker
    Foukakis, Theodoros
    Bergh, Jonas
    CANCER, 2020, 126 (06) : 1175 - 1182
  • [30] Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and metaanalysis of randomised controlled trials
    Xu, Zhi-Qiao
    Zhang, Yan
    Li, Ning
    Liu, Pei-Jie
    Gao, Ling
    Gao, Xin
    Tie, Xiao-Jing
    BMJ OPEN, 2017, 7 (03):
12345